Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: | Neurology | Psychiatry/Psychology
Search Medical Condition
Memory Loss Clinical Trials
A listing of Memory Loss medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Found (63) clinical trials
A Phase 2 Multiple Dose, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Subjects With Early Alzheimer's Disease.
This study seeks to evaluate the efficacy and safety of ABBV-8E12 in subjects with Early Alzheimer's Disease.
A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study to Evaluate the Efficacy and Safety of E2609 in Subjects With Early Alzheimer's Disease
The name of this trial is MissionAD1. This 24-month treatment, multicenter, double-blind, placebo-controlled, parallel group, Phase 3 study in participants with Early Alzheimer's Disease (EAD) including mild cognitive impairment (MCI) due to AD/Prodromal AD and the early stages of mild AD will be conducted to evaluate the efficacy and safety ...
Cognite Trial – A Phase III Safety and Efficacy Study of ALZT-OP1 in Individuals with Evidence of Early Alzheimer’s Disease
This Phase III study is designed as a randomized, double-blinded, placebo-controlled study for subjects with evidence of early AD. The study will evaluate safety and tolerability, efficacy as measured by CDR-SB, and will determine if the combination therapy ALZT-OP1 will slow down, arrests, or reverse cognitive and functional decline in ...
A Multi-center, Double-blind, Randomized, Placebo-controlled Study for the Efficacy of Phosphatidylserine in Mild Cognitive Impairment (MCI)
The primary objective is to evaluate the efficacy and safety of phosphatidylserine (PS) on cognitive abilities in MCI
A study to evaluate the efficacy and safety of E2609 in individuals with early Alzheimer's disease
The MISSION-AD study is investigating the efficacy and safety of an investigational drug on symptoms of cognitive decline in individuals with mild cognitive impairment or early Alzheimer's disease. The study drug is a tablet which is taken by mouth once per day. The study will last approximately two years. Eligibility ...
A study investigating the effect of crenezumab infusion on Alzheimer's disease progression in individuals with prodromal or mild Alzheimer's disease.
Study Description: CREAD2 is a Phase 3 study investigating the effect of an investigational drug in the form of an infusion on Alzheimer's disease progression in individuals with prodromal to mild Alzheimer's disease. The study drug, crenezumab, is a monoclonal antibody that targets amyloid-beta proteins in the brain. The study ...
Mild Dementia/Alzheimer's Disease
Northern California Research is enrolling participants for a Mild Dementia/Alzheimer's Disease study. The purpose of this study is to see if daily doses of a study medication will improve the symptoms of mild dementia due to Alzheimer's disease. This study medication has been designed to change the cortisol levels in ...
Clinical Research for Patient with Mild Cognitive Impairment due to Alzheimer's Disease or Mild to Moderate Alzheimer’s Disease disease
If you qualify, the study may involve 3 screening visits, 1 separate in-clinic stay of 5 days/4 nights and 10 outpatient visits. All study exams and procedures are provided at no cost to you. You do not need medical insurance to participate.
A Phase 3, double blind, randomized study of RVT-101 versus placebo when added to existing stable donepezil treatment in subjects with mild to moderate Alzheimer’s disease; RVT-101-3001
This Study is for patients that have mild to moderate Alzheimer's disease that are on a stable therapy with donepezil.
Clinical study evaluating treatment for Alzheimer's disease
The purpose of this study is to evaluate Donepezil and Memantine for the treatment of Alzheimer's disease.
